URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00392548
• Date of registration: 25/10/2006
• Primary sponsor: Tel-Aviv Sourasky Medical Center
• Public title: URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol
• Scientific title: Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
• Date of first enrolment: October 2006
• Target sample size: 130
• Recruitment status: Not yet recruiting
• URL: http://clinicaltrials.gov/show/NCT00392548
• Study type: Observational
• Study design: Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective

Countries of recruitment

Israel

Contacts

• Name: Deborah T Blumenthal, MD

• Name: Deborah T Blumenthal, MD
• Affiliation: Tel-Aviv Sourasky Medical Center

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation
therapy.

- Patient must meet the eligibility requirements for the RTOG treatment study. (If the
patient is deemed retrospectively ineligible for the RTOG treatment study, the
patient will likewise be ineligible for this study.)

- Patient must sign a study-specific informed consent for RTOG 0611 prior to study
entry.

Exclusion Criteria:

- Patient not able to receive 6000 cGy of radiation therapy.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Glioblastoma

Secondary ID(s)

RTOG0611

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

RTOG